Asymmetric and symmetric dimethylarginine in patients presenting with risk factors for coronary heart disease

• Authors: Marina Ilic , Radmila Pavlovic , Gordana Lazarevic , Tatjana Cvetkovic , Gordana Kocic , Stevan Ilic , Vladisav Stefanovic
• Languages of publication: EN

Abstracts

EN

The aim of the present study was to investigate asymmetric (ADMA) and symmetric dimethylarginine (SDMA) production in patients presenting with one or more risk factor (RF) for coronary heart disease (CHD). Patients and methods: Overall, 113 participants were enrolled in the study, including 45 patients presenting with risk for CHD (27 male and 18 female; aged 55.9 ± 6.4 years), 30 sex and age-matched middle-aged healthy controls (16 male and 14 female; aged 56.3 ± 8.4 years), and 38 young healthy controls (38 male; aged 24.6 ± 3.9 years). Results: No significant differences for ADMA and SDMA were recorded between patients groups presenting with risk for CHD. However, ADMA and SDMA were significantly higher in all examined patient groups (≥3 and 1–2 RF, hypertensive and non-hypertensive, obese and non-obese, diabetics and non-diabetics) compared with both control groups (middle-aged and young controls) (p<0.001). ADMA significantly correlated with SDMA in ≥3 RF (p<0.05), hypertensive (p<0.05), non-obese (p<0.05), non-diabetics (p<0.01), as well in middle-aged (p<0.05) and young controls (p<0.001). Conclusion: Significantly higher ADMA and SDMA were found between patients presenting with risk for CHD (≥3 and 1–2 RF, hypertensive and nonhypertensive, obese and non-obese, diabetics and non-diabetics) and healthy, middle-aged and young controls. ADMA significantly correlated with SDMA in ≥3 RF, hypertensive, non-obese and non-diabetic patients, as well as in middle-aged and young controls.

Keywords

EN

Nitric oxide; Asymmetric and symmetric dimethylarginine; Coronary heart disease

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2012
• Volume: 7
• Issue: 5
• Pages: 659-664

Dates

published

1 - 10 - 2012

online

28 - 7 - 2012

Contributors

author

Marina Ilic

• Institute of Cardiology, Niska Banja, Faculty of Medicine, University of Nis, 18000, Nis, Serbia

author

Radmila Pavlovic

• Institute of Chemistry, Faculty of Medicine, University of Nis, 18000, Nis, Serbia

author

Gordana Lazarevic

• Clinic of Cardiology, Clinical Center, Nis, 18000, Nis, Serbia

author

Tatjana Cvetkovic

• Institute of Biochemistry, Faculty of Medicine, University of Nis, 18000, Nis, Serbia

author

Gordana Kocic

• Institute of Biochemistry, Faculty of Medicine, University of Nis, 18000, Nis, Serbia

author

Stevan Ilic

• Institute of Cardiology, Niska Banja, Faculty of Medicine, University of Nis, 18000, Nis, Serbia

author

Vladisav Stefanovic

• Institute of Nephrology, Faculty of Medicine, University of Nis, 18000, Nis, Serbia

References

• [1] Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109(II): 27–33
• [2] Valkonen V, Päivä H, Salonen J, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127–2128 http://dx.doi.org/10.1016/S0140-6736(01)07184-7[Crossref]
• [3] Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–2012 http://dx.doi.org/10.1056/NEJM199312303292706[Crossref]
• [4] Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119:1592–1600 http://dx.doi.org/10.1161/CIRCULATIONAHA.108.838268[WoS][Crossref]
• [5] Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, Stefanadis C, Channon KM. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 2009; 30:1142–1150 http://dx.doi.org/10.1093/eurheartj/ehp061[WoS][Crossref]
• [6] Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with Type 2 diabetes. Diabetes Care 2007; 30: 1834–1839 http://dx.doi.org/10.2337/dc07-0019[WoS]
• [7] Meinitzer, Seelhorst U, Wellnitz B, Schernthaner G. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007; 53:273–283 http://dx.doi.org/10.1373/clinchem.2006.076711[Crossref]
• [8] Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006; 184: 383–388 http://dx.doi.org/10.1016/j.atherosclerosis.2005.05.002[Crossref]
• [9] Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004; 53:1574–1579 http://dx.doi.org/10.1016/j.metabol.2004.06.026[Crossref]
• [10] Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, Winkelmann BR, März W. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011; 57:112–121 http://dx.doi.org/10.1373/clinchem.2010.150854[Crossref][WoS]
• [11] Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via storeoperated calcium influx in monocytes. Nephrol Dial Transplant 2009; 24:1429–1435 http://dx.doi.org/10.1093/ndt/gfn670[Crossref][WoS]
• [12] Kiechl S, Lee T, Santer P, Thompson G, Tsimikas S, Egger G, Holt DW, Willeit J, Xu Q, Mayr M. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009; 205:261–265 http://dx.doi.org/10.1016/j.atherosclerosis.2008.10.040[WoS][Crossref]
• [13] Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006; 21:2446–2451 http://dx.doi.org/10.1093/ndt/gfl292[Crossref]
• [14] Paroni R, Fermo I, Fiorina P, Cighetti G. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids 2005; 28: 389–94 http://dx.doi.org/10.1007/s00726-005-0191-z[Crossref]
• [15] Deljanin Ilic M, Ilic S, Lazarevic G, Kocic G, Pavlovic R, Stefanovic V. Impact of reversible myocardial ischaemia on nitric oxide and asymmetric dimethylarginine in patients with high risk for coronary artery disease. Med Sci Monit 2010; 16:CR394–404
• [16] Böger R, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-An update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60:481–487 http://dx.doi.org/10.1016/j.phrs.2009.07.001[Crossref]
• [17] Cable DG, Celotto AC, Barbosa Evora PR, Schaff HV. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects. Med Sci Monit 2009; 15:248–253
• [18] Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, Wu G. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006; 49:351–359 http://dx.doi.org/10.1007/s00125-005-0066-6[Crossref]
• [19] Cetinalp-Demircan P, Can A, Bekpinar S, Unlucerci Y, Orhan Y. Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease. Endocrine 2007; 31:100–104 http://dx.doi.org/10.1007/s12020-007-0005-z[WoS][Crossref]
• [20] Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 201–1203 http://dx.doi.org/10.1016/S0002-9149(01)02063-X[Crossref]
• [21] Candido R, Zanetti M. Endothelial dysfunction in diabetic vascular disease, Ital Heart J 2005; 6: 703–720
• [22] Lenzen H, Tsikas D, Böger RH. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol 2006; 62: 45–49 http://dx.doi.org/10.1007/s00228-005-0014-x[Crossref]

Identifiers

DOI

10.2478/s11536-012-0031-y